. 2012 Oct 2;7(10):e46143. doi: 10.1371/journal.pone.0046143

Table 1. Comparative distribution of patient’s demographic, clinical and immunological characteristics in the derivation and validation sets.

	Derivation set, N = 45	Validation set, N = 88	p
Gender W/M (% of women)	9/45 (20%)	9/88 (10%)	0.12
Age at enrollment (years)	35 (18–64)	36 (18–67)	0.71
Estimated time post-infection at M0 (days)	51 (28–98)	55 (28–98)	0.83
Blood CD4⁺ T cells/mm³ (range)	571 (208–1509)	546 (250–1295)	0.94
Plasma viral load (log copies of RNA/ml)	5.03 (2.45–7.21)	4.9 (2.41–7.41)	0.63
IP-10 (pg/ml)	249 (2–1318)	232 (40–2880)	0.79

The main characteristics of the patients are listed here for the time point of enrollment during PHI (M0). For each parameter (except gender), the median values and the range are indicated. Plasma IP-10 concentrations were measured by ELISA at M0. For the derivation set, data are shown for those 45 patients out of 46, whose IP-10 was quantified by ELISA. The validation set comprised 88 patients. There was no significant difference between the two sets for any parameter (p>0.11). W: women, M: men, N: number of patients in each set.